posting velocity //
טוען…
Showing: Israel. Click another pill to switch.
Open now
9
Total active openings across all sites
Δ 28-day
+9
Opens minus closes in the last 28 days
Δ 90-day
+9
Opens minus closes in the last 90 days
posting velocity //
company intel · ai-generated
Updated 1d ago
No reliable information is available to me about an Israeli tech company called Final. It may be a young company, operate under a different public-facing name, or lack significant documentation in the sources available to me. Detailed public information is not available, so no verified facts about founders, products, headcount, or funding can be provided.
key people
Key people for this company are being prepared — they will appear here as soon as available.
Peak: Thu around 09:00. Keep your CV ready for it.
Based on 15 events over 19 days. Green days had more opens than closes, red vice-versa. The dark line is the 7-day rolling average.
role mix //
The green layer is the current share of active openings by role. The grey dashed layer is the 90-day baseline — gaps between them show where the company is shifting its hiring mix.
seniority pyramid //
Distribution of active openings by seniority. The 'unknown' row groups jobs from sources that don't expose seniority.
geography //
Active openings by region. Click a row to see jobs in that area.
time on market //
Median
—
25th pct
4.8 days
75th pct
—
Based on 3 closed jobs and 9 still open (right-censored). Curve is Kaplan-Meier; band is the 95% CI.Low event count — the median will stabilise after ~47 more closures. Until then treat the values as indicative.
Window: 180 days back. Don't read the mean — the long tail biases it. Median and percentiles are the honest summary.
Republish rate
—
Fewer than 10 closures in the window — not enough to compute.
hiring signal · from our data
From our job data · always current
9 open roles in Israel
Top roles
news feed
<p align="justify">TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide pipeline have been accepted for presentation at ENDO 2026, the annual meeting of the Endocrine Society, taking place June 13-16, 2026 in Chicago, Illinois, USA. Notably, new clinical data supporting Entera’s single EB613 tablet as the final candidate for its planned Phase 3 study in postmenopausal women with osteoporosis was selected for a Late Breaking Oral Presentation.</p>
May 28, 2026
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9WWFpMaHVodEltOVhScjM4QUlBN3l1UThTYkE4dUVrQ2xObGVCY0FaRGZpMzlvQWJpM2xBMFFxQTQ0YXBYVi1PMkluYWhfQVFGMXE1bFYzNURaUUkyUVJxSmE5ODV6Zm8?oc=5" target="_blank">Imperva Israel GM exits as Thales finalizes cyber merger</a> <font color="#6f6f6f">CTech</font>
Nov 2, 2025